Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (CTRI/2026/09/117442) titled 'A study to test whether nerandomilast helps people with systemic sclerosis' on Sept. 10.
Study Type: Interventional
Study Design:
Other Method of generating randomization sequence:Other Method of allocation concealment:Other Blinding and masking:Participant and Investigator Blinded
Primary Sponsor: Boehringer Ingelheim
Condition:
Health Condition 1: M34- Systemic sclerosis [scleroderma]
Intervention:
Intervention1: Nerandomilast: Dose: 9 mg
Route: oral
Frequency: Bid
Duration: 52 weeks and up to approximately 191 weeks
Intervention2: Nerandomilast: Dose: 18 mg
Route: oral
Frequency: Bid
Duration...